{
    "clinical_study": {
        "@rank": "18492", 
        "arm_group": [
            {
                "arm_group_label": "Enbrel (etanercept)", 
                "arm_group_type": "Active Comparator", 
                "description": "Enbrel 50mg twice weekly times 12 weeks"
            }, 
            {
                "arm_group_label": "CHS-0214", 
                "arm_group_type": "Experimental", 
                "description": "CHS-0214 50mg twice weekly times 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO\n      who have not yet received any biologic therapy for any indication (other than insulin or\n      hormones)."
        }, 
        "brief_title": "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center\n      global study. The primary end point is 75% improvement from baseline according to the\n      Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and\n      safety at a dosage of 50mg subcutaneous (Sc) twice weekly.\n\n      Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center\n      global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female adults\n\n          -  PsO diagnosis for 6 months\n\n          -  Active disease: PASI greater than or equal to 12, Physician's Static Global\n             Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),\n\n          -  Body Surface Area (BSA) involved with PsO greater than or equal to 10%\n\n          -  Dermatology Life Quality Index (DQLI) greater than or equal to 10\n\n          -  Previously received phototherapy or systemic non-biologic therapy for PsO\n\n        Exclusion Criteria:\n\n          -  Forms of Psoriasis other than PsO\n\n          -  Drug induced Psoriasis\n\n          -  Positive QuantiFERON-tuberculosis (TB) Gold Test\n\n          -  Presence of significant comorbid conditions\n\n          -  Chemistry and hematology values outside protocol specified range\n\n          -  Major systemic infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "424", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134210", 
            "org_study_id": "CHS-0214-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enbrel (etanercept)", 
                "description": "Head-to-head comparison", 
                "intervention_name": "Etanercept", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Enbrel", 
                    "European Enbrel"
                ]
            }, 
            {
                "arm_group_label": "CHS-0214", 
                "intervention_name": "CHS-0214", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "PsO", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Craig Leonardi, M.D.", 
                "phone": "314-721-5565"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63117"
                }, 
                "name": "Central Dermatology"
            }, 
            "investigator": {
                "last_name": "Craig Loenardi, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis", 
        "overall_official": {
            "affiliation": "Coherus Biosciences, Inc.", 
            "last_name": "Barbara K Finck, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PASI-75", 
            "safety_issue": "No", 
            "time_frame": "12-weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134210"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Coherus Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Coherus Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}